To Assess the Effect of 336 Days Exposure of Paractin® on Pain & Disease Progression in Patients Suffering From Osteoarthritis of Knee Joint.
A Double-blind, Randomized, Placebo-controlled Study to Assess the Effect of 336 Days Exposure of Paractin® on Pain & Disease Progression in Patients Suffering From Osteoarthritis of Knee Joint.
Sponsor: Vedic Lifesciences Pvt. Ltd.
A NA clinical study on Knee Osteoarthritis (Knee OA), this trial is completed. The trial is conducted by Vedic Lifesciences Pvt. Ltd. and has accumulated 12 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
-
Sep 2025 — Jan 2026 [monthly]
Completed NA
-
Jun 2025 — Sep 2025 [monthly]
Completed NA
Status: Unknown → Completed
-
Dec 2024 — Jun 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
▶ Show 7 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Dec 2022 — Jul 2024 [monthly]
Recruiting NA
-
Sep 2022 — Dec 2022 [monthly]
Recruiting NA
-
Mar 2022 — Sep 2022 [monthly]
Recruiting NA
-
Oct 2021 — Mar 2022 [monthly]
Recruiting NA
-
Sep 2021 — Oct 2021 [monthly]
Recruiting NA
-
May 2021 — Sep 2021 [monthly]
Recruiting NA
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vedic Lifesciences Pvt. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .